Colon | Rectum, Phase II
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for metastatic disease.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Andrea Brennan
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- M. Sung Lee, MD
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pamela Kunz, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Last Updated04/30/2023
- Study HIC#2000026787